Back to News
Market Impact: 0.2
Beactica Therapeutics selects BEA-28 as a preclinical candidate, a first-in-class TEAD degrader for biomarker-selected cancers
Source: PR Newswire
Healthcare & BiotechCompany FundamentalsTechnology & Innovation
Beactica Therapeutics AB selected BEA-28 as a preclinical candidate for its TEAD programme. The programme aims to develop novel therapies for a range of aggressive conditions; the supplied article text provides no further development details or financial impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
More News
- Why Dangote’s Nigeria Refinery IPO Is Such a Big Deal for Africa
- Singapore's Temasek warns of the ‘biggest risk’ facing markets right now
- A 32% beat, a +6% jump: the IT solutions name our models picked in July
- Nvidia Is on the Verge of a $6 Trillion Market Value
- Controversial $110 billion mega-merger of Paramount and Warner Bros. finally closes
- What Marvell's rosy long-term guidance means for our AI chip stocks